Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 8:5:PO.20.00183.
doi: 10.1200/PO.20.00183. eCollection 2021.

Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer

Swapnil Parmar  1 , Jamie M Keck  1   2 , Ben Kong  1 , Regan Look  3 , Brett Johnson  1   2   4 , Janice Patterson  1 , Marilyne Labrie  1   5 , Alexander R Guimaraes  1   5   6 , Christopher L Corless  1   7 , Carol Beadling  1 , Annette Kolodzie  1   2 , Raymond Bergan  1 , Joe W Gray  1   2   4 , Gordon B Mills  1   5   8 , Zahi I Mitri  1
Affiliations
Case Reports

Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer

Swapnil Parmar et al. JCO Precis Oncol. .
No abstract available

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
(A) Overview of treatment timeline in the metastatic setting with zoomed-in image to show timeline during study enrollment. Graphs show decrease in circulating tumor biomarkers on therapy with trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg once every 3 weeks) and capecitabine (500 mg/m2 PO twice a day 1 week on followed by 1 week off). (B) Pretreatment and post-treatment images showing decrease in multifocal liver metastatic burden on therapy.
FIG 2.
FIG 2.
Reverse-phase protein array (RPPA) shows activation of HER2/HER3 heterodimer by analysis of single protein and pathway signaling. Protein expression values were normalized within the TCGA breast cancer. The data were z-scored and pathway activity was assessed using pathway scores calculated as described previously. The histogram represents the distribution of the single protein/phosphoprotein or the pathway activity of the TCGA breast cancer cohorts and SMMART cohort as well as the pathway activity of the patient’ sample (black line). HER3, total HER3 protein; HER3 pY1289, phosphorylated HER3; HER2, total HER2 protein; HER2 pY1248, phosphorylated HER2; RTK, receptor tyrosine kinase pathway (cMET_pY1235, EGFR_pY1173, HER2_pY1248, HER3_pY1289, IGF1R_pY1135_Y1136, IRS1, Src_pY527, SHP-2_pY542, Shc_pY317, Src_pY416); PI3K_AKT, PI3 kinase-AKT pathway (Akt_pS473, Akt_pT308, GSK3αβ_pS21S9, p27_pT198, PRAS40_pT246, PTEN).
See this image and copyright information in PMC

References

    1. Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers Cancer Cell 23603–6172013 - PubMed
    1. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: Receptor heterodimerization in development and cancer EMBO J 193159–31672000 - PMC - PubMed
    1. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nat Med 23703–7132017 - PMC - PubMed
    1. Choudhury NJ, Campanile A, Antic T, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations J Clin Oncol 342165–21712016 - PMC - PubMed
    1. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. - PMC - PubMed

Publication types